BNTC NASDAQ
Benitec Biopharma Inc.
1W: +2.8%
1M: -10.4%
3M: -27.8%
YTD: -27.1%
1Y: -38.6%
3Y: +190.2%
5Y: -87.0%
$8.68
+0.09 (+1.05%)
After Hours: $8.81 (+0.13, +1.56%)
Weekly Expected Move ±9.0%
$7
$8
$9
$9
$10
Credit Risk of going bust: lower than 83% of companies Debt: 0.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Benitec Biopharma Inc. would be worth roughly what it owes.
Total debt $762K against a stock market value of $299.7M.
Distance to default 10.41 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $381K (short-term plus half of long-term), stock volatility 62.7%; Altman Z'' 32.70. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Benitec Biopharma Inc. would be worth roughly what it owes.
Total debt $762K against a stock market value of $299.7M.
Distance to default 10.41 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $381K (short-term plus half of long-term), stock volatility 62.7%; Altman Z'' 32.70. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$299.7M
52W Range8-16.76
Volume98,628
Avg Volume162,294
Beta0.25
Dividend—
Analyst Ratings
Company Info
CEOJerel A. Banks
Employees24
SectorHealthcare
IndustryBiotechnology
IPO Date2014-06-24
Websitebenitec.com
3940 Trust Way
Hayward, CA 94545
US
Hayward, CA 94545
US
510 780 0819
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Latest News
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)
Benitec GAAP EPS of -$0.98 in-line
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
60,061 Shares in Benitec Biopharma Limited $BNTC Acquired by Bank of New York Mellon Corp
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BUCHI J KEVIN | G-Gift | 51,813 | — | 2026-06-29 |
| Friedman David Matth | A-Award | 35,000 | $11.45 | 2026-05-26 |
| Friedman David Matth | 0 | — | 2026-05-22 | |
| Mates Sharon | A-Award | 31,500 | $12.83 | 2026-01-22 |
| SUVRETTA CAPITAL MAN | P-Purchase | 65,800 | $13.44 | 2025-12-29 |